Screening of donor and recipient in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 9-21

  Fischer, S A ^a   Lu, K ^b  

^a BROWN UNIVERSITY   (United States)

^b I SHOU UNIVERSITY   (Taiwan)

Author keywords

Donor infection; donor to host transmission; latent infection; prevention; screening; testing

Indexed keywords

ARTICLE; BACTERIAL INFECTION; CADAVER DONOR; CHAGAS DISEASE; CYTOMEGALOVIRUS; DONOR SELECTION; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNIZATION; INFLUENZA A; LIVING DONOR; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PARASITOSIS; PATIENT COUNSELING; PRIORITY JOURNAL; RABIES VIRUS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

BACTERIAL INFECTIONS; HUMANS; LIVING DONORS; ORGAN TRANSPLANTATION; PARASITIC DISEASES; TISSUE DONORS; VIRUS DISEASES;

EID: 84874923486     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12094     Document Type: Article

References (110)

1. Avery RK,. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002; 35: 1513-1519.
2. Avery RK,. Prophylactic strategies before solid-organ transplantation. Curr Opin Infect Dis 2004; 17: 353-356.
3. Delmonico FL,. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 2000; 31: 781-786.
4. Delmonico FL, Snydman DR,. Organ donor screening for infectious diseases: Review of practice and implications for transplantation. Transplant 1998; 65: 603-610.
5. Fischer SA, Avery RK, and the AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9 (Suppl 4): S7-S18.
6. Schaffner A., Pretransplant evaluation for infections in donors and recipients of solid organs. Clin Infect Dis 2001; 33 (Suppl 1): S9-S14.
7. Avery RK, Ljungman P,. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 2001; 33 (Suppl 1): S15-S21.
8. Fishman JA, Nicolas CI,. Infection in organ transplantation: Risk factors and evolving patterns of infection. Infect Dis Clin N Am 2010; 24: 274-283.
9. Patel R, Paya CV,. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10: 86-124.
10. Gottesdiener KM,. Transplanted infections: Donor-to-host transmission with the allograft. Ann Intern Med 1989; 110: 1001-1016.
11. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: Clinical practice guidelines. Am J Transplant 2001; 1 (Suppl 2): 3-95.
12. Kasiske BL, Ravenscraft M, Ramos EL, Gaston RS, Bia MJ, Danovitch GM,. The evaluation of living renal transplant donors. Clinical practice guidelines: Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1996; 7: 2288-2313.
13. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002; 2: 701-711.
14. Chung RT, Feng S, Delmonico FL,. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001; 1: 185-191.
15. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Morb Mortal Wkly Rep 2000; 49: 1-125.
16. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Morb Mortal Wkly Rep 1994; 43: 1-17.
17. Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: Data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9: 1929-1935.
18. Ison MG, Nalesnik MA,. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011; 11: 1123-1130.
19. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005; 352: 1103-1111.
20. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006; 354: 2235-2249.
21. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348: 2196-2203.
22. Simonds RJ, Holmberg SD, Hurwitz RL, et al. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992; 326: 726-732.
23. Ison MG, Llata E, Conover CS, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 2011; 11: 1218-1225.
24. Ahn J, Cohen SM,. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl 2008; 14: 1603-1608.
25. Fishman JA, Strong DM, Kuehnert MJ,. Organ and tissue safety workshop 2007: Advances and challenges. Cell Tissue Bank 2009; 10: 271-280.
26. Strong DM, Seem D, Taylor G, et al. Development of a transplantation transmission sentinel network to improve safety and traceability of organ and tissues. Cell Tissue Bank 2010; 11: 335-343.
27. Fishman JA, Greenwald MA, Kuehnert MJ,. Enhancing transplant safety: A new era in the microbiologic evaluation of organ donors? Am J Transplant 2007; 7: 2652-2654.
28. Humar A, Fishman JA,. Donor-derived infection: Old problem, new solutions? Am J Transplant 2008; 8: 1087-1088.
29. Centers for Disease Control and Prevention. HIV transmitted from a living organ donor-New York City, 2009. Morbid Mortal Wkly Rep 2011; 60: 297-301.
30. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: Is the 'best' test the right test? A consensus conference report. Am J Transplant 2010; 10: 889-899.
31. Cortes NJ, Afzali B, MacLean D, et al. Transmission of syphilis by solid organ transplantation. Am J Transplant 2006; 6: 2497-2499.
32. Doig RL, Boyd PJ, Eykyn S,. Staphylococcus aureus transmitted in transplanted kidneys. Lancet 1975; 2: 243-245.
33. Kumar D, Cattral MS, Robicsek A, Gaudreau C, Humar A,. Outbreak of Pseudomonas aeruginosa by multiple organ transplantation from a common donor. Transplant 2003; 75: 1053-1055.
34. Fernando ON, Higgins AF, Moorhead JF,. Letter: Secondary haemorrhage after renal transplantation. Lancet 1976; 2: 368.
35. Nelson PW, Delmonico FL, Tolkoff-Rubin NE, et al. Unsuspected donor Pseudomonas infection causing arterial disruption after renal transplantation. Transplant 1984; 37: 313-314.
36. Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplant 1999; 68: 1107-1111.
37. Lopez-Navidad A, Domingo P, Caballero F, Gonzalez C, Santiago C,. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplant 1997; 64: 365-368.
38. Ruiz I, Gavalda J, Monforte V, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 2006; 6: 178-182.
39. McCoy GC, Loening S, Braun WE, Magnusson MO, Banowsky LH, McHenry MC,. The fate of cadaver renal allografts contaminated before transplantation. Transplant 1975; 20: 467-472.
40. Mossad SB, Avery RK, Goormastic M, Hobbs RE, Stewart RW,. Significance of positive cultures from donor left atrium and postpreservation fluid in heart transplantation. Transplant 1997; 64: 1209-1210.
41. Matignon M, Botterel F, Audard V, et al. Outcome of renal transplantation in eight patients with Candida sp. contamination of preservation fluid. Am J Transplant 2008; 8: 697-700.
42. Sauget M, Verdy S, Slekovec C, et al. Bacterial contamination of organ graft preservation solution and infection after transplantation. Transpl Infect Dis 2011; 13: 331-334.
43. Singh N, Paterson DL,. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis 1998; 27: 1266-1277.
44. Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7: 2797-2801.
45. Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48: 1276-1284.
46. Antony SJ, Ynares C, Dummer JS,. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997; 11: 34-37.
47. Morris MI, Daly JS, Blumberg E, et al. Diagnosis and management of tuberculosis in transplant donors: A donor derived infections consensus conference report. Am J Transplant 2012; 12: 2288-300.
48. Limaye AP, Connolly PA, Sagar M, et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med 2000; 343: 1163-1166.
49. Tripathy U, Yung GL, Kriett JM, Thistlethwaite PA, Kapelanski DP, Jamieson SW,. Donor transfer of pulmonary coccidioidomycosis in lung transplantation. Ann Thorac Surg 2002; 73: 306-308.
50. Blair JE, Logan JL,. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001; 33: 1536-1544.
51. Wreghitt TG, Gray JJ, Pavel P, et al. Efficacy of pyrimethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patients. Transpl Int 1992; 5: 197-200.
52. Rogers NM, Peh CA, Faull R, Pannell M, Cooper J, Russ GR,. Transmission of toxoplasmosis in two renal allograft recipients receiving an organ from the same donor. Transpl Infect Dis 2008; 10: 71-74.
53. Gourishankar S, Doucette K, Fenton J, et al. The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis. Transplant 2008; 85: 980-985.
54. Chagas disease after organ transplantation-Los Angeles, California, 2006. Morb Mortal Wkly Rep 2006; 55: 798-800.
55. Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: Recommendations from the Chagas in Transplant Working Group. Am J Transplant 2011; 11: 672-680.
56. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG,. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 1997; 126: 275-279.
57. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R,. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Clin Infect Dis 1997; 25: 314-317.
58. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880.
59. Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplant 1998; 66: 1641-1644.
60. Preiksaitis JK, Keay S,. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001; 33 (Suppl 1): S38-S46.
61. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplant 1998; 66: 1604-1611.
62. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS guidelines. Brit J Haematol 2010; 149: 675-692.
63. Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplant 1999; 67: 399-403.
64. Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339: 1358-1363.
65. Gomez-Roman JJ, Ocejo-Vinyals JG, Sanchez-Velasco P, Leyva-Cobian F, Val-Bernal JF,. Presence of human herpesvirus 8 DNA sequences in renal transplantation-associated pleural Kaposi sarcoma. Arch Pathol Lab Med 1999; 123: 1269-1273.
66. Kapelushnik J, Ariad S, Benharroch D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma. Br J Haematol 2001; 113: 425-428.
67. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplant 1995; 59: 230-234.
68. Madayag RM, Johnson LB, Bartlett ST, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplant 1997; 64: 1781-1786.
69. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ,. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplant 1999; 68: 1058-1061.
70. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Jr., Straffon RA,. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplant 1999; 67: 272-275.
71. Pinney SP, Cheema FH, Hammond K, et al. Acceptable recipient outcomes with the use of hearts from donors with hepatitis B core antibodies. J Heart Lung Transplant 2005; 24: 34-37.
72. Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD,. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38: 1074-1081.
73. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998; 53: 1374-1381.
74. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999; 30: 1293-1298.
75. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8: 355-365.
76. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 2004-2014.
77. Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS). Guidance for HTLV-1 screening and confirmation in potential donors and reporting potential HTLV-1 infection. Published online 6/29/2011, accessed at http://optn.transplant.hrsa.gov/ SharedContentDocuments/Guidance- DTAC-HTLV-06 - 2011.pdf on August 12, 2012.
78. Ad Hoc Disease Transmission Advisory Committee (DTAC). Proposal to modify requirements for mandatory HTLV-1/2 testing for all potential deceased donors. Accessed at http://optn.transplant.hrsa.gov/PublicComment/pubcommentPropSub-252. pdf on August 12, 2012.
79. Marvin MR, Brock GN, Kwarteng MS, et al. Increasing utilization of human T-cell lymphotropic virus (+) donors in liver transplantation: Is it safe? Transplant 2009; 87: 1180-1190.
80. Nowicki MJ, Marsuoka L, Brucal D, et al. High seroprevlance of anti-HTLV-I/II antibodies among solid organ donors necessitates confirmatory testing. Transplant 2006; 82: 1210-1213.
81. Kaul DR, Taranto S, Alexander C, et al. Donor screening for human T-cell phymophtropic virus 1/2; changing paradigms for changing testing capacity. Am J Transplant 2010; 10: 207-213.
82. Toro C, Rodes B, Poveda E, Soriano V,. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplant 2003; 75: 102-104.
83. Zarranz Imirizaldu JJ, Gomez Esteban JC, Rouco Axpe I, et al. Post-transplantation HTLV-1 myelopathy in three recipients from a single donor. J Neurol Neurosurg Psychiatry 2003; 74: 1080-1084.
84. Gonzalez-Perez MP, Munoz-Juarez L, et al. Human T-cell leukemia virus type I infection in various recipients of transplants from the same donor. Transplant 2003; 75: 1006-1011.
85. Nakamura N, Tamaru S, Ohshima K, Tanaka M, Arakaki Y, Miyauchi T,. Prognosis of HTLV-I-positive renal transplant recipients. Transplant Proc 2005; 37: 1779-1782.
86. Fischer SA., Emerging viruses in transplantation: There is more to infection after transplant than CMV and EBV. Transplant 2008; 86: 1327-1339.
87. Kumar D, Humar A,. Emerging viral infections in transplant recipients. Curr Opin Infect Dis 2005; 18: 337-341.
88. Update: Investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion-Michigan, 2002. Morb Mortal Wkly Rep 2002; 51: 879.
89. Kiberd BA, Forward K,. Screening for West Nile virus in organ transplantation: A medical decision analysis. Am J Transplant 2004; 4: 1296-1301.
90. Centers for Disease Control and Prevention. Lymphocytic choriomeningitis virus infection in organ transplant recipients-Massachusetts, Rhode Island, 2006. Morb Mortal Wkly Rep 1005; 543 (dispatch): 1-2.
91. Brief report: Lymphocytic choriomeningitis virus transmitted through solid organ transplantation-Massachusetts, 2008. Morb Mortal Wkly Rep 2008; 57: 799-801.
92. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008; 358: 991-998.
93. Amman BR, Pavlin BI, Albarino CG, et al. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. Emerg Infect Dis 2007; 13: 719-725.
94. MacNeil A, Stroher U, Farnon E, et al. Solid organ transplant-associated lymphocytic choriomeningitis, United States, 2011. Emerg Infect Dis 2012; 18: 1256-1262
95. Update: Interim guidance for minimizing risk for human lymphocytic choriomeningitis virus infection associated with pet rodents. Morb Mortal Wkly Rep 2005; 54: 799-801.
96. Kusne S, Smilack J,. Transmission of rabies virus from an organ donor to four transplant recipients. Liver Transpl 2005; 11: 1295-1297.
97. Kumar D, Tellier R, Draker R, Levy G, Humar A,. Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003; 3: 977-981.
98. Gavada J, Cabral E, Alonso E, et al. Influenza A H1N1/2009 infection in pediatric solid organ transplant recipients. Transpl Infect Dis 2012; 0: 1-5.
99. Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10: 18-25.
100. Cho JH, Kim CD, Kim MS, et al. The impact of A (H1N1) pdm09 infection on renal transplant recipients: A multicenter cohort study. J Infect 2012; 65: 88-90.
101. Halliday N, Wilmore S, Griffiths PD, et al. Risk of transmission of H1N1 influenza by solid organ transplantation in the United Kingdom. Transplantation 2012; 93: 551-554.
102. Cockbain AJ, Jacob M, Ecuyer, et al. Transplantation of solid organs procured from influenza A H1N1 infected donors. Transpl Int 2011; 24: e107-e110
103. Fishman JA,. New technologies for infectious screening of organ donors. Transplant Proc 2011; 43: 2443-2445.
104. Herrmann M, Wetand M, Greshake B, et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 1997; 95: 814-817.
105. Simon D, Fischer S, Grossman A, et al. Left ventricular assist device-related infection: Treatment and outcome. Clin Infect Dis 2005; 40: 1108-1115.
106. Avery RK., Infections after lung transplantation. Semin Respir Crit Care Med 2006; 27: 544-551.
107. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH,. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164: 2102-2106.
108. Remund KF, Best M, Egan JJ,. Infections relevant to lung transplantation. Proc Am Thorac Soc 2009; 6: 94-100.
109. Broussard V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in cystic fibrosis patients colonized with Burkoldheria cepacia complex; results from two French centers. Thorax 2008; 63: 732-737.
110. Mazurek GH, Villarino ME,. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. Morb Mortal Wkly Rep 2003; 52: 15-18.